The Food and Drug Administration (FDA) is asking for public comments on its data collection efforts related to the Biosimilars User Fee Program, which supports the development of biosimilar drugs. The program, part of the Biologics Price Competition and Innovation Act, helps guide the approval process for biosimilars by allowing companies to pay user fees to the FDA. These fees are collected to ensure the safe and effective development of these drugs. Companies interested in participating should submit comments by March 5, 2025, and can find more information on the FDA's website.
Simple Explanation
The FDA wants to know what people think about collecting money from companies to help make new medicines that are similar to ones they already sell. This money is used to make sure the new medicines are safe and effective.